Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
The research logic is that combining amylin receptor activation (cagrilintide) with GLP-1 receptor activation (semaglutide) engages two complementary metabolic signaling pathways
Proper storage of Semaglutide / Methylcobalamin ODT is essential for maintaining the stability and potency of this compounded medication throughout its designated beyond-use date
Gomes et al
The ZAGUTA Glutathione Drip is not just any treatment
We are executing with focus and discipline, and the momentum across our programs continues to accelerate as we move closer to bringing this product candidate to patients who need it most. Advancing Toward Value-Driving Catalysts in 2026 Fractyl is advancing toward multiple anticipated clinical readouts from the ongoing REMAIN weight maintenance program: January 2026: 6-month randomized data from the REMAIN-1 Midpoint Cohort Q2 2026: 1-year REVEAL-1 Cohort data Q3 2026: 1-year REMAIN-1 Midpoint Cohort data H2 2026: Topline 6-month randomized data from REMAIN-1 Pivotal Cohort H2 2026: Potential Revita PMA filing in post-GLP-1 weight maintenance About REVEAL-1 The REVEAL-1 Cohort (n=22) is an open-label study in individuals living with obesity who have lost at least 15% of their total body weight on a GLP-1 medication and who either need or choose to discontinue GLP-1 therapy
